Blog
RSS FeedPosted by Michael Wonder on 07 Mar 2023
PHARMAC funds two new treatments for lung cancer
7 March 2023 - PHARMAC has announced the funding of two new medicines - pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for people ...
Posted by Michael Wonder on 07 Mar 2023
PHARMAC announces decision to fund Trikafta
7 March 2023 - Pharmac has today confirmed the funding of elexacaftor with tezacaftor and ivacaftor (Trikafta) for people with cystic ...
Posted by Michael Wonder on 05 Mar 2023
Our progress in the funding of medicines for rare disorders
3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...
Posted by Michael Wonder on 03 Mar 2023
'Death sentence' for mum with skin cancer without $100k for the drugs she needs
3 March 2023 - Jen Rowlands, 43, faces certain death from terminal cancer without a specific drug that could radically improve ...
Posted by Michael Wonder on 03 Mar 2023
PHARMAC releases final response to review
3 March 2023 - "There are 30 actions we committed to in the interim response – these are part of ...
Posted by Michael Wonder on 02 Mar 2023
PHARMAC confirms widened access for the funded flu vaccine
2 March 2023 - PHARMAC is widening access to the annual funded flu vaccine to tamariki aged 6 months to 12 ...
Posted by Michael Wonder on 28 Feb 2023
New Zealand Pharmaceutical Schedule - 1 March 2023
1 March 2023 - The March 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Feb 2023
PHARMAC will fund meningococcal B vaccine for babies, teens and young people
28 February 2023 - From Wendesday, PHARMAC will fund meningococcal B vaccine for a number of potentially at-risk groups including ...
Posted by Michael Wonder on 28 Feb 2023
“Killing time” one year on, still no final response from PHARMAC to the independent review
28 February 2023 - Today marks one year since the PHARMAC Review was delivered to then Health Minister Andrew Little. ...
Posted by Michael Wonder on 21 Feb 2023
PHARMAC signals first step towards funding continuous glucose monitors
21 February 2023 - PHARMAC will soon be seeking competitive commercial offers for the supply of funded continuous glucose monitors ...
Posted by Michael Wonder on 21 Feb 2023
PHARMAC's communications approach for the Trikafta consultation
21 February 2023 - To be transparent about its approach, PHARMAC has released information, including a communications plan and correspondence ...
Posted by Michael Wonder on 10 Feb 2023
PHARMAC to get one time $66 million boost
10 February 2023 - The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash ...
Posted by Michael Wonder on 31 Jan 2023
New Zealand Pharmaceutical Schedule - 1 February 2023
1 February 2023 - The February 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Jan 2023
Pharmaceuticals campaigner moving to Australia after drug she desperately needs for spinal muscular atrophy is only funded for under 18s
22 January 2023 - This week, PHARMAC announced it was looking to fund a second drug to treat the neurological ...
Posted by Michael Wonder on 18 Jan 2023
PHARMAC seeking feedback on funding a second spinal muscular atrophy treatment
19 January 2023 - PHARMAC is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (Evrysdi) for ...